In addition, NCP26 induced dose-dependent growth inhibition at EC50 values in the range of 350–680 nM in CD138+ tumour cells from three MM patients, with a considerably lower inhibitory effect towards PBMCs (EC50 27–36 μM) or CD40 antibody- and IL-4-stimulated B cells (EC50 > 20 μM) from healthy volunteers (Fig. 3E). This evidence concerns the gene CD40 and Miyoshi myopathy.